Los Angeles, California

SYMPOSIUM INFORMATION

>General Information
>Faculty
>Program/Schedule
>Accreditation
>Registration
>Hotel Reservations
>Privacy Policy

 

Supported by:
PIH Health Good Samaritan Hospital
Los Angeles, CA


Officially Endorsed by:
American College of Cardiology
California Chapter


FIFTH ANNUAL SYMPOSIUM

Contemporary Management of
Cardiovascular Disease in Women

April 23, 2022
Omni Los Angeles Hotel
Los Angeles California

PROGRAM / SCHEDULE

Saturday, April 23

6:45     Registration Opens

6:55-7:55     Breakfast

6:55-7:55
Product Theatre (Non-CME)
A treatment option for appropriate HFrEF patients following a
worsening HF event

     Highlight the burden of HFH in patients with HFrEF.
     Review a treatment option for reducing the risk of HFH and
       CV death in appropriate patients with HFrEF.

    Dr. Catherine Marti
    Piedmont Heart Institute - Athens, Georgia

    Supported by: Merck

Please Pre-Register for this Online Presentation by clicking on this link:
> Register

Once registered please use the link sent to your e-mail to access the program. If participants pre-register prior to the event they can avoid waiting for the link during the actual presentation.

8:05-8:10
Introductory Remarks

8:10-8:35
Cardiovascular Disease in Women: 2022 Update
    Christina Economides, MD, MM, FSCAI

8:35-9:00
Cardiovascular Consequences of COVID: Acute and Long-term
    Shira Shafir, PhD, MPH

9:00-9:25
Microvascular Disease: INOCA and MINOCA Update 2022
    Janet Wei, MD, FACC

9:25-9:50
Effect of Diabetes on Cardiovascular Outcomes in Women
    Karol Watson, MD, PhD

9:50-10:05
Question & Answer

10:05-10:20     Break

10:20-10:45
Current Management of Pulmonary Arterial Hypertension
    Shelley Shapiro, MD, PhD, FACC

10:45-11:10
Cardio-Obstetrics: The Management of Cardiovascular Complications in Pregnancy
    Priya Pillutla, MD

11:10-11:35
Update on Dyslipidemia Management in Women
    Margo B Minissian, PhD, ACNP, CLS, AACC, FAHA

11:35-12:00
Effect of Intermittent Fasting and Diet on Cardiovascular Outcomes
    Christina Craigo, MSN, ACNP, AACC

12:00-12:15
Question & Answer

12:30-1:30     Lunch
Product Theatre (Non-CME)
Addressing Elevated Risk For Thrombotic CV Events in
Patients Across the CAD Spectrum

     Understand the risk factors that contribute to the elevated risk for thrombotic cardiovascular events pre- and post-myocardial infarction in patients across the coronary artery disease spectrum.
     Differentiate oral P2Y12 inhibitors with respect to their clinical pharmacology and examine the select differences between oral antiplatelet therapies.
     Describe the role of BRILINTA in reducing the risk of cardiovascular events in patients with acute coronary syndrome, history of myocardial infarction, and high-risk coronary artery disease without prior myocardial infarction.

    Warren Fegenbush, PharmD, BCPS

    Supported by: AstraZeneca Pharmaceuticals, LP

1:40-2:05
Atrial Fibrillation in Women
    Anil Bhandari, MD, FACC, FHRS

2:05-2:30
Heart Failure Management in Women: Current Landscape and Pharmacologic Management
    Joseph Rahman, MD

2:30-2:55
Heart Failure Management in Women: Current Cardiac Device Considerations
    Ravi Sureddi, MD

2:55-3:20
The Era of TAVR: What is the role of SAVR?
    Katrine Zhiroff, MD, FACC, FSCAI

3:20-3:35
Question & Answer

3:35-3:50     Break

3:50-4:15
Transcutaneous Mitral Valve Repair (TMVR):
Are There Gender Differences?
    Christina Economides, MD, MM, FSCAI

4:15-4:40
Pushing the Limits of Structural Heart Disease
    Steven Burstein, MD

4:40-5:20
Major Cardiovascular Trials of 2019/2020/2021
Case-Based Presentations
Moderators:
    Christina Economides, MD, MM, FSCAI
    Katrine Zhiroff, MD, FACC, FSCAI

5:20-5:25     Adjourn